drugset / Trial / NCT05327621
Pamiparib in mCRPC With HRD or BRCA1/2 Mutation
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy of a PARP inhibitor, Pamiparib, in metastatic castration-resistant prostate cancer patients with homologous recombination deficiency or BRCA 1 or 2 somatic/germline mutation.
Timeline
- Start
- 2022-05-01
- Primary completion
- 2025-03-20
- Completion
- 2025-03-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pamiparib | Small molecule | 40 mg | Oral |